Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes

Biochemical Pharmacology

Volumn 67, Issue 3, 2004, Pages 427-437

  Roymans, Dirk ^a   Van Looveren, Cis ^a   Leone, Angelique ^b   Parker, J Brandon ^b   McMillian, Michael ^b   Johnson, Mark D ^b   Koganti, Aruna ^c   Gilissen, Ron ^d   Silber, Paul ^c   Mannens, Geert ^a   Meuldermans, Willem ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON   (United States)

^c In Vitro Technologies Inc   (United States)

^d ADME/TOX   (Belgium)

Author keywords

CYP1A2; CYP3A4; Cytochrome P450; Gene and protein expression; Human hepatocytes; Induction

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; ETHOXYRESORUFIN; OMEPRAZOLE; RIFAMPICIN; ROSIGLITAZONE; TESTOSTERONE DERIVATIVE;

ARTICLE; CONCENTRATION RESPONSE; CRYOPRESERVATION; HUMAN; HUMAN CELL; IMMUNODETECTION; INCUBATION TIME; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROIDOGENESIS; UPREGULATION;

EID: 10744233944     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.09.022     Document Type: Article

References (35)

1. Smith D.A. Induction and drug development. Eur. J. Pharm. Sci. 11:2000;185-189.
2. Li A.P. Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions. Adv. Pharmacol. 43:1997;103-130.
3. Freeman D.J., Laupacis A., Keown P.A., Stiller C.R., Carruthers S.G. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br. J. Clin. Pharmacol. 18:1984;887-893.
4. DeSouza M.J., Pollock S.H., Solomon H.M. Cyclosporine-phenytoin interaction. Drug Metab. Disp. 16:1988;256-258.
5. Cooney G.F., Mochon M., Kaiser B., Dunn S.P., Goldsmith B. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Pharmacotherapy. 15:1995;353-356.
6. Breckenridge A., Orme M. Clinical implications of enzyme induction. Ann. NY Acad. Sci. 179:1971;421-431.
7. Silva J.M., Morin P.E., Day S.H., Kennedy B.P., Payette P., Rushmore T., Yergey J.A., Nicoll-Griffith D. Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metab. Disp. 26:1998;490-496.
8. LeCluyse E.L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13:2001;343-368.
9. Donato M.T., Castell J.V., Gomez-Lechon M.J. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Disp. 23:1995;553-558.
10. Ferrini J.B., Pichard L., Domergue J., Maurel P. Long-term primary cultures of adult human hepatocytes. Chem. Biol. Interact. 107:1997;31-45.
11. Guillouzo A., Morel F., Langouet S., Maheo K., Rissel M. Use of hepatocyte cultures for the study of hepatotoxic compounds. J. Hepatol. 26:1997;73-80.
12. Kern A., Bader A., Pichlmayr R., Sewing K.F. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem. Pharmacol. 54:1997;761-772.
13. Maurel P. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv. Drug Deliv. Rev. 22:1996;105-132.
14. Skett P., Tyson C., Guillouzo A., Maier P. Report on the international workshop on the use of human liver preparations to study drug metabolism in drug development. Biochem. Pharmacol. 50:1995;280-285.
15. Alexandre E., Viollon-Abadie C., David P., Gandillet A., Coassolo P., Heyd B., Mantion G., Wolf P., Bachellier P., Jaeck D., Richert L. Cryopreservation of adult human hepatocytes obtained from resected liver biopsies. Cryobiology. 44:2002;103-113.
16. Hengstler J.G., Ringel M., Biefang K., Hammel S., Milbert U., Gerl M., Klebach M., Diener B., Platt K.L., Böttger T., Steinberg P., Oesch F. Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction. Chem. Biol. Interact. 125:2000;51-73.
17. Hengstler J.G., Utesch D., Steinberg P., Platt K.L., Diener B., Ringel M., Swales N., Fischer T., Biefang K., Gerl M., Böttger T., Oesch F. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab. Rev. 32:2000;81-118.
18. Li A.P., Gorycki P.D., Hengstler J.G., Kedderis G.L., Koebe H.G., Rahmani R., de Sousas G., Silva J.M., Skett P. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem. Biol. Interact. 121:1999;117-123.
19. Li A.P., Roque M.A., Beck D.J., Kaminski D.L. Isolation and culturing of hepatocytes from human liver. J. Tissue Cult. Methods. 14:1992;139-146.
20. Loretz L.J., Li A.P., Flye M.W., Wilson A.G. Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica. 19:1989;489-498.
21. Ruegg C.E., Silber P.M., Mughal R.A., Ismail J., Lu C., Bode D.C., Li A.P. Cytochrome-P450 induction and conjugated metabolism in primary human hepatocytes after cryopreservation. In Vitro Toxicol. 10:1997;217-222.
22. Gellner K., Eiselt R., Hustert E., Arnold H., Koch I., Haberl M., Deglmann C.J., Burk O., Buntefuss D., Escher S., Bishop C., Koebe H.G., Brinkmann U., Klenk H.P., Kleine K., Meyer U.A., Wojnowski L. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenomics. 11:2001;111-121.
23. Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparanta T., Mayer R.T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450. Biochem. Pharmacol. 34:1985;3337-3345.
24. Easterbrook J., Fackett D., Li A.P. A comparison of Aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethlyation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4′-hydroxylation, chlorzoxazone 6-hydroxylation and testosterone 6β-hydroxylation. Chem. Biol. Interact. 134:2001;243-249.
25. Curi-Pedrosa R., Daujat M., Pichard L., Ourlin J.C., Clair P., Gervot L., Lesca P., Domergue J., Joyeux H., Fourtanier G., Maurel P. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 269:1994;384-392.
26. Sahi J., Hamilton G., Sinz M., Barros S., Huang S.M., Lesko L.J., LeCluyse E.L. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica. 30:2000;273-284.
27. Donato M.T., Gómez-Lechón M.J., Jover R., Nakamura T., Castell J.V. Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isoenzymes in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther. 284:1998;760-767.
28. Guillén M.I., Donato M.T., Jover R., Castell J.V., Fabra R., Trullenque R., Gómez-Lechón M.J. Oncostatin M down-regulates basal and induced cytochromes P450 in human hepatocytes. J. Pharmacol. Exp. Ther. 285:1998;127-134.
29. Lindley C., Hamilton G., McCune J.S., Faucette S., Shord S.S., Hawke R.L., Wang H., Gilbert D., Jolley S., Yan B., LeCluyse E.L. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab. Disp. 30:2002;814-821.
30. Luo G., Cunningham M., Kim S., Burn T., Lin J., Sinz M., Hamilton G., Rizzo C., Jolley S., Gilbert D., Downey A., Mudra D., Graham R., Carroll K., Xie J., Madan A., Parkinson A., Christ D., Selling B., LeCluyse E., Gan L.-S. Cyp3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Disp. 30:2002;795-804.
31. Pascussi J.-M., Drocourt L., Gerbal-Chaloin S., Fabre J.-M., Maurel P., Vilarem M.-J. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Eur. J. Biochem. 268:2001;6346-6357.
32. Gremse D.A. Lansoprazole: pharmacokinetics. Expert Opin. Pharmacother. 2:2001;1663-1670.
33. Prueksaritanont T., Vega J.M., Zhao J., Gagliano K., Kuznetsova O., Musser B., Amin R.D., Liu L., Roadcap B.A., Dilzer S., Lasseter K.C., Rogers J.D. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J. Clin. Pharmacol. 41:2001;573-581.
34. Mamidi N.V.S.R., Mullangi R., Katneni K., Ravikanth B., Babu A.P., Rani U.P., Naidu M.U.R., Srinivas N.R., Rajagopalan R. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J. Clin. Pharmacol. 42:2002;670-675.
35. Budde K., Neumayer H.-H., Fritsche L., Sulowicz W., Stompôr T., Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br. J. Clin. Pharmacol. 55:2003;368-374.